32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses thereof
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRachel Meyers, William James Cook
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acids molecules, designated DHDR nucleic acid molecules, which encode novel DHDR-related dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR gene has been introduced or disrupted. The invention still further provides isolated DHDR proteins, fusion proteins, antigenic peptides and anti-DHDR antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
Claims49
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10;
- and
- (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:12.
An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.
An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number ______.
An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to the nucleotide sequence of SEQ ID NO:1 or 3, SEQ ID NO:
- 4 or 6, SEQ ID NO:7 or 9, or SEQ ID NO:
- 10 or 12, or a complement thereof;
- b) a nucleic acid molecule comprising a fragment of at least 50 nucleotides of a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or 3, SEQ ID NO:
- 4 or 6, SEQ ID NO:7 or 9, or SEQ ID NO:10 or 12, or a complement thereof;
- c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 60% identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:12;
- and
- d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, wherein the fragment comprises at least 16 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.
An isolated polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, wherein the fragment comprises at least 16 contiguous amino acids of SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of SEQ ID NO:1 or 3, SEQ ID NO:
- 4 or 6, SEQ ID NO:7 or 9, or SEQ ID NO:10 or 12 under stringent conditions;
- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 60% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 4, 6, 7, 9, 10, or 12;
- d) a polypeptide comprising an amino acid sequence which is at least 60% identical to the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:5, SEQ ID NO:8, or SEQ ID NO:11.
A method of identifying a subject having a viral disorder, or at risk for developing a viral disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:10;
- and
- b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a subject having a viral disorder, or at risk for developing a viral disorder.
A method of identifying a subject having a viral disorder, or at risk for developing a viral disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:10 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:10;
- b) incubating said sample under conditions that allow nucleic acid amplification;
- and
- c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a subject having a viral disorder, or at risk for developing a viral disorder.
A method of identifying a subject having a viral disorder, or at risk for developing a viral disorder comprising:
- a) contacting a sample obtained from said subject comprising polypeptides with a DHDR binding substance;
- and
- b) detecting the presence of a polypeptide in said sample that binds to said DHDR binding substance, thereby identifying a subject having a viral disorder or at risk for developing a viral disorder.
A method for identifying a compound capable of treating a viral disorder characterized by aberrant DHDR nucleic acid expression or DHDR polypeptide activity comprising assaying the ability of the compound to modulate DHDR nucleic acid expression or DHDR polypeptide activity, thereby identifying a compound capable of treating a viral disorder characterized by aberrant DHDR nucleic acid expression or DHDR polypeptide activity.
A method for treating a subject having a viral disorder characterized by aberrant DHDR polypeptide activity or aberrant DHDR nucleic acid expression comprising administering to the subject a DHDR modulator, thereby treating said subject having a viral disorder.
Dependencies are inferred from the claim text.